Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Author: CycloLab Ltd.

March 26, 2022 Events

CycloLab awarded by 2021 Innovation Grand Prize

The Hungarian Association of Innovation awarded CycloLab with this prestigious prize due to its meaningful and very profitable innovation concerning

Continue reading

July 2, 2021 Events

CycloLab appoints new leaders in key positions

As CycloLab continues to expand its workforce both in the production and the R&D arms of the company, two new

Continue reading

February 4, 2021 CD as API / Drug delivery / Events

Press Release – Development of Autophagy Inducing Cyclodextrin Derivatives for Aging-associated Diseases

CycloLab Cyclodextrin R&D Ltd. proudly announces winning of a national grant about the development of cyclodextrin-dervatives for autophagy-associated neurodegenerative diseases.

Continue reading

July 25, 2018 CD derivatives

Cyclodextrin Phosphates

In order to develop cyclodextrin derivatives having improved aqueous solubility, high solubilizing power, and low accumulation upon longer administration charged

Continue reading

July 25, 2018 Pharma applications / Supramolecular systems

Nanoaggregation on command

ScienceDaily reported on the effect of cyclodextrins as parts of synthetic receptors on the aggregation of proteins, recently published by

Continue reading

July 25, 2018 CD as API / Events / Pharma applications

Annual National Niemann Pick Disease Foundation Conference

Among several lectures useful for the families with member(s) suffering in rare diseases the ongoing clinical trials for NPC patients

Continue reading

Recent Posts

  • Crystallization inhibition by methylated cyclodextrin
  • Alfa-cyclodextrin MS-signals from Danish Golden Age paintings
  • The mechanism and therapy of aortic aneurysms
  • Pharmacokinetic studies of hyperoside-2-hydroxypropyl-β-cyclodextrin inclusion complex and ameliorated colitis in mice
  • A review on Sulfobutylether-β-cyclodextrin for drug delivery applications

Tags

alpha-CD Alzheimer disease Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems FDA Food Gilead HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Sugammadex Synthesis wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (15)
  • Analysis (37)
  • CD as API (215)
  • CD derivatives (269)
  • Cosmetics and toilettry (22)
  • Diagnosis (1)
  • Drug delivery (461)
  • E-ducation (56)
  • Environmental (80)
  • Events (163)
  • Food (128)
  • Gene delivery (10)
  • In Hungarian (4)
  • Life sciences (19)
  • Non-pharma applications (229)
  • Other industrial use (69)
  • Pharma applications (731)
  • Supramolecular systems (27)
  • Uncategorized (47)

Top Posts

  • The mechanism and therapy of aortic aneurysms
  • Lanosterol eye drops for cataract treatment
  • Alfa-cyclodextrin MS-signals from Danish Golden Age paintings
  • Website of EuroCD Conference is open
  • Practical Considerations about the Cyclodextrin Solubilities – A Quickstart Guide for Newbies
  • Crystallization inhibition by methylated cyclodextrin
  • Green materials with promising applications: Cyclodextrins-based deep eutectic supramolecular polymers
  • GRAS status of CD derivatives
  • Aggregation versus inclusion complexes to solubilize drugs with cyclodextrins. A case study using sulfobutylether-β-cyclodextrins and remdesivir
  • Pharmacokinetic studies of hyperoside-2-hydroxypropyl-β-cyclodextrin inclusion complex and ameliorated colitis in mice

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 552 other subscribers
 

Loading Comments...